Conditional MLL-CBP targets GMP and models therapy-related myeloproliferative disease
Open Access
- 6 January 2005
- journal article
- research article
- Published by Wiley in The EMBO Journal
- Vol. 24 (2), 368-381
- https://doi.org/10.1038/sj.emboj.7600521
Abstract
No abstract availableThis publication has 45 references indexed in Scilit:
- The Oncogene Nup98-HOXA9 Induces Gene Transcription in Myeloid CellsOnline Journal of Public Health Informatics, 2004
- Genome‐wide analysis of acute myeloid leukemia with normal karyotype reveals a unique pattern of homeobox gene expression distinct from those with translocation‐mediated fusion eventsGenes, Chromosomes and Cancer, 2003
- Bethesda proposals for classification of nonlymphoid hematopoietic neoplasms in miceBlood, 2002
- MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemiaNature Genetics, 2001
- Hoxa9 transforms primary bone marrow cells through specific collaboration with Meis1a but not Pbx1bThe EMBO Journal, 1998
- The CBP co-activator is a histone acetyltransferaseNature, 1996
- An Mll–AF9 Fusion Gene Made by Homologous Recombination Causes Acute Leukemia in Chimeric Mice: A Method to Create Fusion OncogenesCell, 1996
- Altered Hox expression and segmental identity in Mll-mutant miceNature, 1995
- Nuclear protein CBP is a coactivator for the transcription factor CREBNature, 1994
- Very high frequency of lymphoma induction by a chemical carcinogen in pim-1 transgenic miceNature, 1989